Bank of America Corp DE Grows Stake in Pulse Biosciences, Inc $PLSE
Bank of America Corp DE has increased its stake in Pulse Biosciences, Inc (NASDAQ:PLSE) by 8.2% in the first quarter, now owning 866,061 shares worth over $18 million. Several other institutional investors also adjusted their positions in PLSE. The article also covers Pulse Biosciences' recent price performance, earnings, and analyst ratings, which currently indicate a "Moderate Buy" consensus.
Pulse Biosciences (PLSE) Launched A $75 Million Offering, Is The Upside Already Priced In?
Pulse Biosciences (PLSE) recently reported wider second-quarter losses and initiated a $75 million equity offering, despite a significant run-up in its share price. The company is advancing its atrial fibrillation nsPFA program, but its current valuation of $46.79 is considered overvalued compared to a narrative fair value of $41.00. Investors are advised to examine key reward and warning signs as the company faces hurdles like ongoing losses and execution risks in converting its pipeline into revenue.
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 18, 2026
Pulse Biosciences announced equity inducement grants to five new employees under Nasdaq Listing Rule 5635(c)(4). These awards, approved by the Compensation Committee, involve options to purchase up to 16,950 shares of common stock at an exercise price of $44.92 per share. The options will vest over four years, contingent on continued employment.
Pulse Biosciences (PLSE) Grants Equity Awards to New Hires Amid High Price-to-Sales Valuation
Pulse Biosciences (PLSE) has granted equity awards to five new hires, totaling options for 16,950 shares, to attract talent crucial for advancing its medical device technologies. The company exhibits an extremely high Price-to-Sales ratio of 2755.9x, indicating strong market expectations despite its unprofitable and cash-flow-negative status. Its GF Score™ is 30/100, reflecting weak profitability and valuation, though tempered by moderate financial strength and strong momentum, while insider buying signals management confidence.
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences, Inc. announced that its Compensation Committee granted equity inducement awards to five new employees. These awards, issued on August 13, 2026, consist of stock options to purchase up to 16,000 shares of common stock at an exercise price of $88.88 per share, vesting over four years. The grants were made outside the Company's 2017 Equity Incentive Plan but under the 2017 Inducement Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Goldman Sachs initiated coverage on Onto Innovation with a Buy rating and a $400 price target, leading a list of five new analyst initiations. Other companies receiving new coverage include Columbia Financial, Target Hospitality, Dave Inc, and Pulse Biosciences, all with bullish ratings and price targets.
PULSE BIOSCIENCES INC : NEEDHAM INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $58
Needham has initiated coverage on Pulse Biosciences Inc. with a Buy rating. The firm has set a target price of $58 for the company's stock. This report was published by Reuters on August 17, 2026.
Pulse Biosciences (PLSE) Is Up 5.0% After Wider Losses And $75M ATM Plan Filed – Has The Bull Case Changed?
Pulse Biosciences recently reported wider net losses for Q2 and H1 2026 and filed for a $75 million at-the-market equity offering, indicating increased cash needs and reliance on equity financing. While the company's stock rose 5.0% post-announcement, these developments highlight potential dilution risks and the need for significant R&D spending to translate into revenue from its nanosecond pulse field ablation platforms. The investment narrative hinges on clinical trial success, with analysts now reconsidering earlier bullish revenue forecasts due to deeper losses and fresh equity.
Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform
Pulse Biosciences is developing nanosecond pulsed field ablation (nsPFA) technology as a potential treatment for atrial fibrillation (AFib) and other conditions. CEO Paul LaViolette highlighted the non-thermal nature of nsPFA, which aims to ablate cells without causing inflammation or damage to surrounding tissues, potentially offering significant advantages over current methods. The company is enrolling its Nano-Pulse AF IDE study in the U.S., building on promising European feasibility study results that showed a substantial reduction in AFib failure rates compared to existing technologies.
Pulse Biosciences, Inc (NASDAQ:PLSE) Given Average Rating of "Moderate Buy" by Brokerages
Pulse Biosciences, Inc. (NASDAQ:PLSE) has received a "Moderate Buy" consensus rating from five analysts, with an average 12-month price target of $45.25. The company's stock opened at $44.54, near its 52-week high, and institutional investors hold a significant portion of its shares. Despite positive analyst sentiment, Pulse Biosciences recently reported an adjusted loss of $0.36 per share, missing expectations, and analysts project a full-year loss of $1.29 per share.
Needham & Company LLC Initiates Coverage on Pulse Biosciences (NASDAQ:PLSE)
Needham & Company LLC initiated coverage on Pulse Biosciences (NASDAQ:PLSE) with a "Buy" rating and a $58 price target, indicating a potential upside of over 30%. Despite missing quarterly earnings and revenue expectations, the company holds a "Moderate Buy" consensus rating from analysts. Institutional investors own a significant portion of the stock, and the company focuses on developing medical devices using its proprietary Tissue NanoPoration (TNP) platform.
Pulse Biosciences (PLSE) Stock Looks Pricey On Book Value Yet Strong On Returns
Pulse Biosciences (PLSE) stock has seen a significant run, returning 431.5% over three years, driven by its atrial fibrillation program. Despite this strong performance, the stock appears expensive based on traditional valuation metrics, trading at a P/B of 31.9x compared to an industry average of 2.6x. The market is pricing in substantial future clinical and commercial success, making the stock highly sensitive to trial outcomes and regulatory approvals.
Pulse Biosciences (PLSE) Is Up 5.0% After Wider Losses And $75M ATM Plan Filed – Has The Bull Case Changed?
Pulse Biosciences recently reported widened net losses for Q2 and H1 2026 and filed for a US$75 million at-the-market equity offering, signaling increased cash needs. While these developments raise concerns about cash burn and dilution risk, the core investment narrative around its nanosecond pulse field ablation platforms and ongoing clinical trials, such as the NANOPULSE AF study reaching its enrollment midpoint, remains central. The article questions if the new financial details alter the long-term bullish outlook for the company, which anticipates significant revenue growth by 2029.
(PLSE) Risk Channels and Responsive Allocation
This article provides an in-depth AI-driven analysis for Pulse Biosciences Inc (NASDAQ: PLSE), highlighting strong sentiment across all horizons and compelling upside potential. It details institutional trading strategies with specific entry zones, targets, and stop losses for position trading, momentum breakout, and risk hedging. The analysis also includes multi-timeframe signal strengths, support, and resistance levels.
Pulse Biosciences (PLSE) Prices A $75 Million Offering, Is The Stock Fully Valued?
Pulse Biosciences (PLSE) recently announced a $75 million at-the-market equity offering and reported wider second-quarter losses, impacting existing shareholders. Despite strong recent share price performance, with a 30-day return of 55.30% and a year-to-date return of 232.64%, the stock now trades above the latest analyst price target. The most popular valuation narrative suggests the stock is 8.6% overvalued, with a fair value of $41 compared to its recent close of $44.54, based on aggressive assumptions about future revenue and margins.
Pulse Biosciences (NASDAQ:PLSE) Sets New 1-Year High - Time to Buy?
Pulse Biosciences (NASDAQ:PLSE) stock reached a new 52-week high of $46.03, closing at $46.75, despite reporting weaker-than-expected quarterly results. Analyst sentiment is mixed, with a "Moderate Buy" consensus but an average price target below the current trading price. Institutional investors hold a significant 76.95% of the company's shares.
Pulse Biosciences stock reaches all-time high at 46.03 USD By Investing.com
Pulse Biosciences Inc. (PLSE) stock hit an all-time high of $46.03, currently trading near its 52-week high of $45.90, despite a recent report of wider-than-expected Q2 2026 losses and lower revenue. The stock has seen a significant 163.78% one-year increase and 216% year-to-date, boosting its market capitalization to $3.24 billion, though InvestingPro indicates it is overvalued. Positive investor sentiment is driven by progress in its atrial fibrillation trial and other programs, leading Canaccord to raise its price target to $43.
Pulse Biosciences stock reaches all-time high at 46.03 USD
Pulse Biosciences (PLSE) stock reached an all-time high of $46.03, currently trading at $45.91. This surge represents a 163.78% increase over the past year and 216% year-to-date, pushing its market capitalization to $3.24 billion. Despite recent financial results showing a wider-than-expected loss and lower revenue, investor sentiment remains positive due to progress in clinical trials and a raised price target from Canaccord.
PLSE: nsPFA technology delivers breakthrough efficacy in AFib and is poised for broad clinical adoption
Pulse Biosciences, Inc. (PLSE) is developing next-generation nsPFA technology for AFib treatment, demonstrating high efficacy and efficiency. The company's leadership, strong clinical data, competitive position, and partnership strategy are expected to drive broad clinical adoption. This information is based on an audio transcript from Canaccord Genuity's 46th Annual Growth Conference.
Canaccord Genuity Group Issues Positive Forecast for Pulse Biosciences (NASDAQ:PLSE) Stock Price
Canaccord Genuity Group has increased its price target for Pulse Biosciences (NASDAQ:PLSE) from $32 to $43, reaffirming a "Buy" rating, despite the company reporting weaker-than-expected quarterly results. The stock holds a "Moderate Buy" consensus rating from analysts with an average target of $36. Institutional ownership in Pulse Biosciences remains high at 76.95%, with significant new investments from firms like BlackRock.
Pulse Biosciences (PLSE) After NANOPULSE AF Progress As Valuation Questions Build
Pulse Biosciences (PLSE) is under scrutiny after reporting a wider quarterly net loss and a US$75 million equity offering, despite its NANOPULSE-AF Study reaching its enrollment midpoint. The stock has seen significant gains, but analysts are concerned about its valuation, with a fair value estimate of $30.67 against a current price of $42.41, indicating it might be overvalued. The narrative for growth relies on rapid revenue expansion and improved margins, but execution risks and limited current revenue pose challenges.
Pulse Biosciences Q2 Earnings Call Highlights
Pulse Biosciences reported Q2 revenue of $434,000, driven by the acceleration of its nanosecond pulsed field ablation (nsPFA) technology for atrial fibrillation. The company's U.S. NANOPULSE-AF pivotal study is ahead of schedule, with enrollment expected to complete in early October, and it is also advancing its surgical clamp and Vybrance thyroid programs. Despite a widening GAAP net loss of $24.7 million due to increased clinical spending, Pulse Biosciences raised $57.5 million in net proceeds through its at-the-market program, extending its operating runway through planned clinical and regulatory milestones.
Pulse Biosciences (NASDAQ:PLSE) Stock Rating Lowered by Wall Street Zen
Wall Street Zen has downgraded Pulse Biosciences (NASDAQ:PLSE) from "hold" to "sell," despite a broader analyst consensus of "Moderate Buy" with an average price target of $32.33. The company's stock opened at $42.41, up 10.9%, but it missed analyst expectations for its last quarterly earnings, reporting a loss of $0.36 per share and revenue of $0.43 million. Insiders currently own 74% of the stock, while institutional investors hold 76.95%.
Pulse Biosciences (NASDAQ:PLSE) Trading Up 15.7% - Should You Buy?
Pulse Biosciences (NASDAQ:PLSE) experienced a 15.7% surge in its stock price, reaching approximately $44.26, despite a 51% drop in trading volume. The company holds a "Moderate Buy" consensus from analysts, though its average price target of $32.33 is below the current share price. This rise occurred after the company reported a wider-than-expected quarterly loss and lower-than-anticipated revenue.
PULSE BIOSCIENCES, INC. 2026: Revenue $434K, EPS ($0.36) — 10-Q Summary
PULSE BIOSCIENCES, INC. reported product revenue of $434K and a net loss of ($24.66M) or diluted loss per share of ($0.36) for the current quarter of 2026. This compares to no product revenue and a ($19.17M) net loss or ($0.28) per share in the prior-year quarter. The company is shifting its focus to electrophysiology (AF) catheters and cardiac devices, has positive clinical data for its nPulse cardiac catheter, and raised equity to fund accelerated AF development.
Form 8K Pulse Biosciences Inc For: 6 August By Investing.com
This article announces the filing of a Form 8K by Pulse Biosciences Inc. on August 6th. The brief notice from Investing.com indicates that the information pertains to the company's financial activities or significant events as required by the SEC.
Pulse Biosciences Q2 Earnings Call Highlights
Pulse Biosciences reported Q2 revenue of $434,000 and is accelerating clinical development of its nsPFA technology, particularly for atrial fibrillation treatment. The company's U.S. NANOPULSE-AF pivotal study is ahead of schedule, with increased enrollment targets and broadened patient eligibility. Despite widening losses due to increased clinical spending, the company's cash and cash equivalents rose to $101.6 million, supported by recent financing efforts.
Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results
Pulse Biosciences announced its business updates and financial results for the second quarter ended June 30, 2026, highlighting significant progress in its cardiac catheter program. The company surpassed the halfway point of enrollment in its U.S. pivotal NANOPULSE-AF study, raising $46.8 million in net proceeds through an ATM program. Total revenue for the quarter was $0.4 million, with a GAAP net loss of ($24.7) million.
Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Misses Revenue Estimates
Pulse Biosciences (PLSE) reported a Q2 loss of $0.36 per share, missing the Zacks Consensus Estimate of a $0.31 loss and underperforming the previous year's loss of $0.28 per share. The company also missed revenue estimates, posting $0.43 million against a 38% higher Zacks Consensus Estimate. Despite the Q2 misses, PLSE shares have seen a significant 176% increase year-to-date, significantly outperforming the S&P 500's 12.8% gain.
Pulse Biosciences enters $75 million equity distribution agreement with Mizuho
Pulse Biosciences has entered into an equity distribution agreement with Mizuho Securities USA LLC, allowing it to offer and sell up to $75 million in common stock. Mizuho will act as the sales agent, receiving a commission of up to 3.0% on shares sold. This news follows several positive developments for the company, including raised price targets from Oppenheimer and Canaccord Genuity, as well as significant insider stock purchases.
Pulse Biosciences Q2 2026 Earnings Call Transcript
Pulse Biosciences (PLSE) reported its Q2 2026 earnings, highlighting significant progress in its NANOPULSE-AF pivotal study, which is ahead of schedule with over 82 evaluable patients. The company strengthened its balance sheet with $101.6 million in cash, extending its financial runway through key clinical and regulatory milestones. Despite increased spending due to accelerated clinical and product development, positive clinical and workflow feedback for its nPulse cardiac catheter suggests strong market adoption potential.
Pulse Biosciences Inc (PLSE) (Q2 2026) Earnings Call Highlights: Accelerated Enrollment and ...
Pulse Biosciences Inc (PLSE) reported accelerated enrollment in its NanoPulse-AF IDE study, reaching the halfway point ahead of schedule, with strong feasibility data presented at HRS. The company strengthened its balance sheet by raising $57.5 million, extending its financial runway, and is progressing multiple programs including a surgical clamp and the Vibrance thyroid system. Despite these positive developments, PLSE continues to incur significant operating losses and faces challenges related to increased enrollment targets, reliance on limited clinical sites, lengthy regulatory approval timelines, minimal revenue generation, and shareholder dilution from capital raising.
Earnings call transcript: Pulse Biosciences misses Q2 2026 estimates but gains on trial progress
Pulse Biosciences reported a wider-than-expected Q2 2026 loss and lower revenue but saw its stock rise after hours due to accelerated enrollment in its atrial fibrillation trial, a stronger cash position, and progress in its thyroid and surgical programs. The company's nanosecond pulsed field ablation (nsPFA) technology is showing promising clinical results, particularly in its cardiac catheter program, with enrollment ahead of schedule and strong physician enthusiasm. Despite the earnings miss, investors are focusing on the company's clinical execution and long-term potential in a complex capital-raising environment.
Pulse Biosciences Inc (PLSE) (Q2 2026) Earnings Call Highlights: Accelerated Enrollment and ...
Pulse Biosciences Inc (PLSE) reported accelerated enrollment in its NanoPulse-AF IDE study, reaching over 82 patients and expecting early Q4 2026 completion. The company showcased strong feasibility data with high freedom from AF and low adverse events, alongside positive physician feedback on procedure speed. Despite widening operating losses and shareholder dilution from capital raises, PLSE is advancing multiple programs and exploring partnerships for market entry.
Earnings Flash (PLSE) Pulse Biosciences, Inc. Reports Q2 Revenue $0.4M, vs. FactSet Est of $533K
Pulse Biosciences, Inc. (PLSE) reported its Q2 revenue at $0.4 million, falling short of FactSet's estimated $533K. The company's stock, PLSE, is listed on Nasdaq in the Advanced Medical Equipment & Technology sector. The article also highlights recent news, including their Q2 earnings call, progress in a pivotal study, and analyst rating adjustments.
Pulse Biosciences earnings on deck as PFA technology faces test By Investing.com
Pulse Biosciences Inc. is expected to report its second-quarter results after market close on Thursday, with investors keenly watching the performance of its Nanosecond Pulsed Field Ablation (PFA) technology. Analysts anticipate a loss of 29 cents per share on revenue of $533,330, reflecting sequential revenue growth but a wider loss compared to the previous quarter. The focus will be on whether the strong clinical data from initial studies can be replicated in larger pivotal trials and the trajectory of commercial adoption for its novel technology.
Pulse Biosciences earnings on deck as PFA technology faces test
Pulse Biosciences is set to report Q2 results, with investors focusing on the efficacy of its Nanosecond Pulsed Field Ablation (PFA) technology in ongoing pivotal trials. Analysts are bullish on the company, despite its pre-profitability status, as they await confirmation that early compelling clinical data can be replicated in larger studies. The report will likely provide updates on trial progress and the pathway to market adoption for this differentiated technology.
(PLSE) Movement as an Input in Quant Signal Sets
This article from Stock Traders Daily discusses Pulse Biosciences Inc (NASDAQ: PLSE), highlighting strong sentiment across all horizons and compelling upside potential. It presents three AI-generated trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, tailored for different risk profiles. The analysis also includes multi-timeframe signal analysis, showing strong signals across near-term, mid-term, and long-term horizons.
Why Pulse Biosciences (PLSE) Is Up 6.4% After NANOPULSE-AF Trial Hits Enrollment Midpoint And What It Means
Pulse Biosciences (PLSE) saw its stock rise 6.4% after its NANOPULSE-AF pivotal study for atrial fibrillation reached its enrollment midpoint, demonstrating rapid recruitment and clinician enthusiasm for its nPulse System. This milestone provides clearer insight into future pivotal data, which could impact reimbursement and guideline inclusion. Despite the positive news, investors are urged to consider the company's financial forecasts, which project significant revenue growth by 2029 but also highlight a potential 19% downside to its current price based on fair value estimates.
Pulse Biosciences Inc expected to post a loss of 36 cents a share - Earnings Preview
Pulse Biosciences Inc (PLSE) is expected to report a loss of 36 cents per share, according to this earnings preview. The article from Reuters indicates this forecast without providing further details on the company's financial performance or future outlook.
Why Pulse Biosciences (PLSE) Is Up 6.4% After NANOPULSE-AF Trial Hits Enrollment Midpoint And What It Means
Pulse Biosciences (PLSE) saw its stock rise by 6.4% after its NANOPULSE-AF Study for atrial fibrillation reached its enrollment midpoint, demonstrating rapid recruitment and clinician enthusiasm. This development is seen as supportive for near-term cardiac data catalysts, potentially influencing future reimbursement and guideline inclusion. While the rapid enrollment is positive, the article reminds investors to consider risks related to clinical outcomes, regulatory review, and commercial adoption, alongside the company's significant cash burn.
Pulse Biosciences stock hits 52-week high at 36.79 USD By Investing.com
Pulse Biosciences Inc. (PLSE) stock hit a new 52-week high of $36.79, reflecting a 138% return over the past year and 156% year-to-date gains. Despite this performance, InvestingPro analysis suggests the stock might be overvalued, noting high volatility and unlikelihood of profitability this year. Recent company developments include a warrant redemption plan and analyst upgrades, with insider buying by top executives totaling $13.3 million.
Enterprise value to EBITDA forward of Pulse Biosciences, Inc – NASDAQ:PLSE
This article provides the enterprise value to EBITDA forward for Pulse Biosciences, Inc. (NASDAQ: PLSE). It also lists the company's trading information on the Nasdaq Stock Market and provides links to its financials, documents, news, and other market data.
Pulse Biosciences (PLSE) Passes AF Study Milestone As Investors Weigh An Overvalued Narrative
Pulse Biosciences (PLSE) has reached a significant milestone in its NANOPULSE-AF Study, with its nPulse System for atrial fibrillation quickly passing the enrollment midpoint. This clinical progress has fueled a strong rally in its share price, with substantial returns over the last 7, 90 days, and three years. Despite its clinical advancements and market value, the stock is considered 15% overvalued compared to fair value estimates, prompting investors to weigh the risks against potential rewards.
Canaccord Genuity Keeps Their Buy Rating on Pulse Biosciences (PLSE)
Canaccord Genuity analyst William Plovanic reiterated a Buy rating on Pulse Biosciences (PLSE) and set a price target of $32.00. This follows Oppenheimer also maintaining a Buy rating with a $35.00 price target. The company recently reported a quarterly revenue of $401 thousand and a GAAP net loss of $18.58 million, while corporate insider sentiment for the stock is positive with an increase in insider buying.
Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference
Pulse Biosciences, Inc. announced its participation in Canaccord Genuity's 46th Annual Growth Conference. Management is scheduled to present on Tuesday, August 11, at 2:30 pm ET, with a live and recorded webcast available on the company's investor website. The company will discuss its Nanosecond Pulsed Field Ablation (nano-PFA) technology and its application in health innovation, including for atrial fibrillation treatment.
Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference
Pulse Biosciences, Inc. (Nasdaq: PLSE) announced its participation in the Canaccord Genuity 46th Annual Growth Conference in Boston, MA. The company's management is scheduled to present on Tuesday, August 11, at 2:30 pm ET, with a live and recorded webcast available on its investor website. Pulse Biosciences is focused on leveraging its proprietary Nanosecond Pulsed Field Ablation (nano-PFA) technology for health innovation, including the treatment of atrial fibrillation.
Pulse Biosciences (PLSE.US) squeeze baby squeeze
The user "Papacito" posted a short message about Pulse Biosciences (PLSE.US), suggesting a potential "squeeze." The post was made in the moomoo Community, which offers educational content and discussions for investors. The article briefly mentions leading technology companies and their stock performance.
PLSE|Pulse Biosciences Inc|Price:34.270|Chg%:-1.200
TradingKey provides a comprehensive stock analysis for Pulse Biosciences Inc (PLSE), highlighting its strong fundamentals, high growth potential, and "Buy" analyst rating. The company's CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology is noted as a key innovation, with high institutional ownership and healthy financial indicators contributing to its positive outlook, despite current technicals suggesting sideways trading.
Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study
Pulse Biosciences has announced that its NANOPULSE-AF IDE Pivotal Study, investigating its Nanosecond Pulsed Field Ablation (nano-PFA) technology for atrial fibrillation, has surpassed its enrollment midpoint since commencing in April 2026. The rapid enrollment is attributed to the enthusiasm of investigational sites for the technology's potential to offer durable pulmonary vein isolation, procedural efficiency, and safe patient outcomes. The company will provide further updates during its upcoming earnings conference call on August 6th.
